GeNeuro and Verily Collaborate to Advance Long-COVID Research
Geneva, Switzerland, October 19, 2023 – 8:00 AM CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an Alphabet precision health technology company, to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein (W-ENV) in SARS-CoV-2 infection. https://geneuro.com/data/news/GeNeuro-PR-Verily-collaboration-19-10-2023-ENG.pdf